Cytokinetics Launches Clinical Trial of Revolutionary Cardiac Myosin Inhibitor to Expand Cardiovascular Therapies

Cytokinetics, Inc. (Nasdaq: CYTK) is excited to announce that the first participants have been successfully dosed in a Phase 1 clinical study of CK-4021586 (CK-586)! CK-586 is a revolutionary cardiac myosin inhibitor that could potentially offer a treatment for patients suffering from heart failure with preserved ejection fraction (HFpEF).

This study is a randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical trial designed to examine the safety, tolerability, and pharmacokinetics of the drug. We are optimistic that this trial will bring us one step closer to providing patients with a much-needed treatment option!

Cytokinetics is proud to announce the commencement of its Phase 1 clinical trial for CK-586 – a revolutionary cardiac myosin inhibitor with a distinct mode of action from aficamten. With this unique mechanism of action, CK-586 may be able to target the hypercontractility present in patients suffering from heart failure with preserved ejection fraction. We are excited to embark on this clinical trial and explore the potential of this promising new therapy.

Phase 1 Clinical Trial Design

This Phase 1 randomized, double-blind, placebo-controlled clinical study seeks to evaluate the safety, tolerability and pharmacokinetics of CK-586 when administered orally as single or multiple doses to healthy participants.

Up to eight single ascending dose cohorts of 10 participants each, and four multiple-dose ascending cohorts of 10 participants each will be evaluated. An optional final cohort of twelve participants in an open-label, two-period crossover arm will investigate the effect of food on CK-586. Join us as we explore the potential of CK-586 in this exciting study!

About CK-4021586

CK-4021586 (CK-586) is a groundbreaking, orally-administered small molecule designed to reduce the contractile force of the heart in sufferers of heart failure with preserved ejection fraction (HFpEF).

By inhibiting the activity of cardiac myosin, CK-586 has been shown to reduce cardiac hypercontractility in preclinical models without affecting calcium transients. This promising new drug offers hope to those struggling with HFpEF and may revolutionize the treatment of this condition.

About Cytokinetics

Cytokinetics is a cutting-edge biopharmaceutical powerhouse, focused on discovering and developing revolutionary treatments for debilitating diseases involving compromised cardiac muscle performance. As a leader in muscle biology and mechanics, the company is engineering small molecule drug candidates to directly target and improve myocardial muscle function and contractility.

Aficamten, their next-in-class cardiac myosin inhibitor, is currently being evaluated in clinical trials for obstructive and non-obstructive hypertrophic cardiomyopathy. Omecamtiv mecarbil, a cardiac muscle activator, is being designed to treat heart failure, and other novel compounds such as CK-3828136 and CK-4021586 are being created to potentially treat HFrEF and other types of heart failure. As Cytokinetics embarks on its 25th year anniversary, the company looks back on a history of pioneering innovation and progress towards a healthier future.

Leave a Comment